Revvity stock leans on its diagnostics and discovery base.
Revvity Inc. (ISIN US76155R1086) is a diagnostics and life sciences company whose stock performance relies on its business model centered around consumables, service, and installed systems. This recurring revenue structure helps stabilize demand fluctuations. The company's diverse product portfolio, including immunoassay systems and genetic testing tools, connects it to clinical volume and lab spending trends, and its stock movements are also influenced by general sentiment towards Nasdaq healthcare and life-science suppliers.
Evercore ISI Adjusts Price Target on Revvity to $125 From $110
Evercore ISI has increased its price target for Revvity (NYSE: RVTY) from $110 to $125. The adjustment was published on July 6, 2026, at 09:13 am EDT. This news comes amidst other recent developments for Revvity, including its expansion of the Signals AI Ecosystem and addition to the Russell 2500 Index.
Revvity Inc. strategy supports long-term growth amid evolving life sciences demand
Revvity Inc. is focusing its strategy on diagnostics and life sciences tools to ensure long-term growth, refining its portfolio to serve researchers and clinicians with integrated solutions. The company provides a comprehensive suite of instruments, reagents, and software for areas including genomics, cell biology, and disease testing, aiming to improve health outcomes through better measurement and workflow integration. Revvity Inc. emphasizes balancing recurring revenue from consumables and services with instrument sales, adapting to market demands through continuous innovation, strategic partnerships, and robust customer support to meet the evolving needs of the healthcare and research sectors.
Revvity Inc. highlights its life sciences role as investors weigh long term growth
Revvity Inc. operates as a diversified life sciences and diagnostics company, providing tools and services globally with a focus on long-term growth through recurring revenue and innovation. The company's business model combines capital equipment with consumables and services, serving both research and clinical applications. Revvity trades on a major U.S. exchange, and its valuation reflects expectations for demand in life sciences tools, diagnostic testing, and technological innovation.
Is Revvity’s Claude Integration Deepening Its Software-Led R&D Strategy Enough To Matter For RVTY?
Revvity announced that its Signals Software business joined Anthropic's Model Context Protocol directory, allowing scientists to access Signals AI capabilities through Claude. This move aims to deepen Signals’ role in R&D by integrating Revvity’s governed scientific data with Claude's AI. While supporting Revvity's software-led investment narrative, the article notes that accelerated software growth is crucial to offset challenges in diagnostics and tools, and user adoption of these new AI features remains an open question.
Is Revvity’s Claude Integration Deepening Its Software-Led R&D Strategy Enough To Matter For RVTY?
Revvity's Signals Software business has integrated with Anthropic's Model Context Protocol, allowing scientists to access Signals AI capabilities through Claude. This move aims to deepen Signals' role in research by using Claude as a front-end for Revvity's governed scientific data, supporting the company's software-led R&D strategy. While this integration is seen as a positive step for Revvity (RVTY), its impact on accelerating software growth and offsetting challenges in diagnostics and tools remains an open question for investors.
Revvity Inc. outlines its diagnostics and life-science focus for investors
Revvity Inc. is a global diagnostics and life-science tools company providing solutions for healthcare systems, research institutions, and industrial customers. The company offers a diversified portfolio including clinical diagnostics, laboratory instruments, and imaging solutions, generating recurring revenue from consumables and instruments alongside software-driven data platforms. Revvity operates in a market influenced by healthcare spending, research funding cycles, and innovation, aiming for consistent growth, cost management, and investment in innovation to maintain a strong financial position.
What You Need to Know Ahead of Revvity’s Earnings Release
Revvity, Inc. (RVTY), a life sciences and diagnostics company, is set to report its fiscal 2026 second-quarter results. Analysts anticipate earnings of $1.23 per share, a 4.2% increase year-over-year, and project continued EPS growth for the full fiscal years 2026 and 2027. While Revvity's stock performance has lagged the broader market and peers, Wall Street maintains a "Moderate Buy" rating, with a potential upside of 27.5% from current levels.
What You Need to Know Ahead of Revvity’s Earnings Release
Revvity, Inc. (RVTY) is preparing to release its fiscal 2026 second-quarter results, with analysts expecting earnings of $1.23 per share, a 4.2% increase year-over-year. The company has consistently beaten earnings estimates in the past four quarters. Despite trailing the broader market in stock performance over the last year, Wall Street maintains a "Moderate Buy" rating, with a high price target suggesting a potential 27.5% upside.
What You Need to Know Ahead of Revvity’s Earnings Release
Revvity, a life sciences and diagnostics company, is set to release its fiscal 2026 second-quarter results. Analysts expect the company to report earnings of $1.23 per share, a 4.2% increase year-over-year, and project continued growth for the full fiscal year and into 2027. Despite shares trailing the broader market, Wall Street analysts maintain a "Moderate Buy" rating for RVTY.
Revvity Expands Signals AI With Anthropic Claude Integration
Revvity, Inc. announced the integration of its Signals Software business with Anthropic’s Model Context Protocol (MCP) connectors, allowing scientists to access Signals AI and R&D knowledge through Claude, including Claude Science. This expansion aims to enhance how researchers interact with complex R&D data using natural language, supporting data traceability and scientific accuracy. The collaboration is expected to strengthen Revvity's position in the AI-enabled research informatics market, drive wider adoption of Signals Software, and contribute to long-term growth in life sciences.
Revvity Expands Signals AI With Anthropic Claude Integration
Revvity's Signals Software business has integrated with Anthropic's Model Context Protocol (MCP) connectors, allowing scientists to access Signals AI and R&D knowledge through Claude, including Claude Science. This expansion beyond the Signals One platform enables researchers to combine Claude's reasoning capabilities with Revvity's governed data and scientific context, addressing the challenge of providing AI models with trusted scientific data. The integration aims to drive wider adoption of Signals Software and reinforce Revvity's leadership in AI-enabled research informatics, benefiting from the growing AI in life sciences analytics market.
Revvity Inc. focuses on life sciences tools as investors weigh long-term growth prospects
Revvity Inc. is a global provider of diagnostics and life sciences tools, serving research and clinical markets with a portfolio including instruments, reagents, software, and services. The company's business model combines upfront instrument sales with recurring revenue from consumables and services, benefiting from long-term secular trends like population aging and increased focus on disease detection. Investors are assessing its potential for steady expansion, balanced against competitive pressures, regulatory complexities, and the need for continuous innovation in its diverse end markets.
Revvity Expands Signals AI With Anthropic Claude Integration
Revvity's Signals Software business has integrated with Anthropic's Model Context Protocol (MCP), allowing scientists to access Signals AI and R&D knowledge through Claude. This expansion aims to enhance AI-enabled research informatics by securely connecting Claude's reasoning capabilities with Revvity's governed scientific data. The company's stock, RVTY, saw a 1.4% gain following the announcement, reflecting positive market sentiment for this strategic move into the growing AI in life science analytics market.
Revvity Inc. stock underperforms Wednesday when compared to competitors despite daily gains
Revvity Inc. (RVTY) shares rose 1.42% to $112.84 on Wednesday, marking its second consecutive day of gains. This occurred during a generally poor trading session where the S&P 500 Index (SPX) fell 0.22% and the Dow Jones Industrial Average (DJIA) fell 0.03%. Despite its daily increase, Revvity underperformed against its competitors as the broader market declined.
Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration
Revvity Signals Software has joined Anthropic's directory for Model Context Protocol (MCP) connectors, allowing scientists to access Signals AI alongside their R&D knowledge through Claude. This integration enables Claude to securely access scientific data via Signals' intelligence layer, improving context-aware analysis. The collaboration aims to accelerate scientific research by combining Anthropic's AI capabilities with Revvity Signals' trusted scientific workflows and governed data.
Revvity Connects Signals Research Platform to Anthropic Claude
Revvity Signals Software has integrated its Signals Research Platform with Anthropic's Claude AI model, enhancing scientific research capabilities. This collaboration allows scientists to interact with R&D data using natural language through an AI workbench called Claude Science, making complex data analysis more accessible. The integration aims to accelerate research and development by combining AI's reasoning with governed, context-rich scientific data managed by Revvity's offerings.
Revvity adds Signals connector to Anthropic’s Claude platform
Revvity Inc. (NYSE:RVTY) announced that its Revvity Signals Software business has integrated a Signals connector into Anthropic's Claude AI platform for Model Context Protocol. This integration allows scientists to access, search, and analyze R&D data using natural language, extending Signals AI's reach beyond its proprietary platform. The connector facilitates combining Claude's reasoning capabilities with governed, ontology-driven scientific data, maintaining traceability for researchers.
Revvity adds Signals connector to Anthropic’s Claude platform By Investing.com
Revvity Inc. has integrated its Signals Software business with Anthropic’s Claude AI platform through a new Model Context Protocol connector. This integration allows scientists to access and analyze R&D data using natural language within Claude, leveraging Signals AI's capabilities for governed data and scientific context. The move aims to enhance decision-making and action in critical health science research and development.
Revvity lets scientists tap R&D data in Claude through new connector
Revvity's Signals Software business has integrated with Anthropic's Claude AI, enabling scientists to securely access and interact with R&D data and knowledge using natural language within Claude. This integration, powered by a new Model Context Protocol (MCP) connector, aims to accelerate scientific research by connecting Claude's reasoning capabilities with trusted, ontology-driven scientific context managed within Revvity Signals AI. The collaboration ensures AI models have access to reliable scientific data, enhancing analysis and decision-making for researchers.
Revvity Inc. stock outperforms competitors despite losses on the day
Shares of Revvity Inc. (RVTY) declined by 1.60% to $111.21 on Monday, marking its second consecutive day of losses. Despite this drop, the stock still outperformed the broader market, which saw the S&P 500 Index (SPX) rise by 1.18% and the Dow Jones Industrial Average (DJIA) increase by 0.59%. This performance highlights Revvity's relative strength in a positive trading session for the overall market.
Revvity, Inc.(NYSE: RVTY) added to Russell 2500 Value Benchmark
Revvity, Inc. (NYSE: RVTY) has been added to the Russell 2500 Value Benchmark, effective June 28, 2026. This news follows a series of recent announcements for the company, including FDA clearance for a total testosterone assay and several quarterly earnings reports and guidance updates for 2026. Revvity specializes in medical diagnosis equipment and analytical instruments, with its net sales distributed across America, Europe, and Asia.
Revvity, Inc.(NYSE: RVTY) added to Russell 2500 Index
Revvity, Inc. (NYSE: RVTY) has been added to the Russell 2500 Index, and also to the Russell 2500 Value Benchmark. The company specializes in medical diagnosis equipment and analytical tools for various sectors, with net sales distributed across America, Europe, and Asia. Upcoming events include an ex-dividend date on July 17.
Price to earnings forward of Revvity, Inc. – NYSE:RVTY
This article displays information related to the price-to-earnings forward metric for Revvity, Inc. (NYSE: RVTY). It indicates that the market was closed at the time of viewing, with no trades recorded. The content primarily consists of navigation links and disclaimers for the TradingView platform.
Immunovant CTO Jay Stout sells $1.53m in company stock
Immunovant CTO Jay Stout sold 40,000 shares of the company’s common stock for over $1.53 million on June 26, 2026. This sale occurred while Immunovant shares were trading near their 52-week high, with InvestingPro analysis suggesting the stock is overvalued. Despite this insider sale, Immunovant has recently received multiple analyst upgrades and positive financial projections following promising clinical trial results and a strong product pipeline.
REVVITY INC : BERNSTEIN RESUMES COVERAGE WITH MARKET-PERFORM RATING; PRICE TARGET $115
Bernstein has resumed coverage of Revvity Inc. (RVTY) with a Market-Perform rating and set a price target of $115. This indicates a neutral outlook on the stock's performance relative to the overall market.
Enterprise value to revenue forward of Revvity, Inc. – NYSE:RVTY
The article presents the "Enterprise value to revenue forward" metric for Revvity, Inc. (NYSE: RVTY) on TradingView. It indicates that the market is closed and there are no current trades for the stock. The page provides an overview of various financial data and community features available on the TradingView platform for the company.
Price to sales forward of Revvity, Inc. – NYSE:RVTY
This article displays the "Price to sales forward" financial metric for Revvity, Inc. (NYSE: RVTY). It provides a view into this specific financial data point for the company, accessible through TradingView. The content is primarily a data placeholder within a financial platform.
ERAS Deadline Alert: The Gross Law Firm Reminds Erasca, Inc. (ERAS) Investors of Securities Class Action Deadline on August 10, 2026
The Gross Law Firm has issued a notice to shareholders of Erasca, Inc. (NASDAQ: ERAS) regarding a securities class action lawsuit. Investors who purchased shares between January 14, 2025, and April 26, 2026, are encouraged to contact the firm, as the deadline to seek lead plaintiff appointment is August 10, 2026. The lawsuit alleges that Erasca made materially false or misleading statements regarding its ERAS-0015 preclinical data.
Price to earnings forward of Revvity, Inc. – DUS:PKN
This article provides financial information for Revvity, Inc. (PKN) on the Dusseldorf Stock Exchange, specifically focusing on its Price to Earnings Forward metric. The content appears to be a stub or a data point within a larger financial platform like TradingView, lacking detailed analytical text or historical data.
Price to sales forward of Revvity, Inc. – DUS:PKN
This page from TradingView displays the "Price to sales forward" for Revvity, Inc. (PKN) on the Dusseldorf Stock Exchange. The core content focuses on financial data for the company, although specific values are not provided in this snippet. The article also mentions the data sources and copyright information.
Bernstein SocGen resumes Revvity stock coverage with Market Perform
Bernstein SocGen has resumed coverage of Revvity Inc. (NYSE:RVTY) with a Market Perform rating and a $115 price target, identifying the company as an "AI loser" in the tools sector due to its preclinical Life Sciences Solutions segment being vulnerable to AI adoption in pharmaceutical R&D. This perspective persists despite the company reporting strong Q1 2026 financial results with earnings and revenue exceeding expectations. Other recent developments include Stifel lowering its price target to $100 and Wolfe Research initiating coverage with a Peerperform rating.
Revvity, Inc. Actuals & Estimates (NYSE:RVTY)
This article provides an overview of Revvity, Inc. (RVTY) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights key metrics such as market capitalization, earnings per share, revenue, and dividend information, summarizing analyst opinions and volatility. The article also covers the company's financial reports, upcoming earnings date, and employee count.
Bernstein SocGen resumes Revvity stock coverage with Market Perform
Bernstein SocGen has resumed coverage on Revvity Inc (NYSE:RVTY) with a Market Perform rating and a $115.00 price target, identifying the company as a potential "AI loser" within the tools sector due to the vulnerability of its preclinical Life Sciences Solutions to AI adoption in pharma R&D. Despite this, Revvity recently reported strong Q1 2026 financial results, exceeding EPS and revenue estimates. Other analysts have adjusted their outlooks, with Stifel lowering its price target and Wolfe Research initiating coverage with a Peerperform rating.
Revvity (RVTY) Coverage Initiated by Bernstein with $115 Target
Bernstein has restarted coverage of Revvity Inc (RVTY) with a Market Perform rating and a $115 price target, citing positive shifts in the life sciences tools and diagnostics sector fueled by increased drug approvals and funding. Despite an optimistic industry outlook, investors are advised to consider Revvity's high P/E ratio and recent insider selling activity, even with its solid GF Score of 75. The company, formed from PerkinElmer's rebranding, supplies reagents and instruments for research and diagnostics globally.
Revvity, Inc. Actuals & Estimates (DUS:PKN)
This article provides an overview of Revvity, Inc. (DUS:PKN) stock performance, financial actuals, and analyst estimates. It includes current stock price, historical highs and lows, market capitalization, volatility, earnings reports, dividend information, and revenue figures. The article also offers insights into analyst forecasts and technical analysis ratings for the stock.
PKN Forecast — Price Target — Prediction for 2027
This article provides a forecast for Revvity, Inc. (PKN) stock, including analyst price targets, current stock performance, and key financial information. It details the company's past earnings, revenue, dividends, and market capitalization, along with technical analysis ratings.
Revvity, Inc. Actuals & Estimates (BMV:RVTY)
The article provides a detailed financial overview and analyst estimates for Revvity, Inc. (BMV:RVTY), including its current stock price, market capitalization, earnings, revenue, and dividend information. It also addresses frequently asked questions about the company's stock performance, future forecasts, and financial reporting.
RVTY Forecast — Price Target — Prediction for 2027
This article provides a stock forecast for Revvity, Inc. (RVTY) on the Mexican Stock Exchange, including analyst price targets, current stock price, historical highs and lows, and volatility. It also details the company's financial performance, such as recent earnings, revenue, net income, market capitalization, and dividend information, along with reporting on the number of employees and EBITDA.
Revvity Inc. stock outperforms competitors on strong trading day
Revvity Inc. (RVTY) shares rose 7.48% to $113.53, marking its third consecutive day of gains. This performance occurred on a mixed trading day where the Dow Jones Industrial Average increased by 0.14% and the S&P 500 Index fell by 0.01%. The article highlights Revvity's stock outperformance relative to the broader market.
3 S&P 500 Stocks We’re Skeptical Of
This article identifies three S&P 500 stocks—3M (MMM), Revvity (RVTY), and Franklin Resources (BEN)—that investors should be wary of, despite their presence in the prominent index. The skepticism stems from issues like stagnant organic revenue growth, declining margins, falling earnings per share, and increased competition. The article suggests these companies have underperformed financially and that better investment opportunities exist.
ERAS INVESTOR DEADLINE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announced an investor class action lawsuit against Erasca, Inc. (ERAS) for alleged violations of the Securities Exchange Act of 1934. The lawsuit claims that Erasca made false or misleading statements regarding its product ERAS-0015, particularly concerning preclinical data comparisons and a patient death during Phase I trials. Investors who purchased Erasca common stock between January 14, 2025, and April 26, 2026, and suffered substantial losses, have until August 10, 2026, to seek appointment as lead plaintiff.
Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss – Hagens Berman
Hagens Berman has announced a securities class action lawsuit against Erasca, Inc. (ERAS) following a significant decline in its stock price. The lawsuit stems from allegations of patent infringement by Revolution Medicines and the death of a patient one month after receiving Erasca's ERAS-0015 treatment. Investors who purchased Erasca common stock between January 14, 2025, and April 26, 2026, and suffered losses are encouraged to contact Hagens Berman.
Revvity Jumps 6.8% Amid Sector-Wide Rally
Revvity, Inc. saw its stock surge by 6.8% on Wednesday, reaching $106.66, as part of a broad sector-wide rally in the diagnostics and research industry. This increase, alongside similar gains experienced by peers like Illumina and Charles River Laboratories, suggests a shift in investor sentiment toward the entire sector rather than company-specific news. Investors are now watching to see if this rally indicates improved fundamentals across the space or is merely a short-term technical bounce.
Revvity Jumps 6.8% Amid Sector-Wide Rally
Revvity, Inc. saw its stock surge 6.8% to $106.66 on Wednesday, as a broad rally positively impacted the diagnostics and research sector. This movement appears to be driven by a sector-wide sentiment shift, with several peers also experiencing significant gains, rather than company-specific news. Investors are advised to monitor whether this rally signifies a lasting trend or a short-term upswing.
Revvity Inc. stock outperforms competitors on strong trading day
Shares of Revvity Inc. (RVTY) rose 5.74% on Wednesday, closing at $105.63. This performance outpaced the broader market, as the Dow Jones Industrial Average saw a slight gain and the S&P 500 Index experienced a minor decline. This marked the second consecutive day of gains for Revvity's stock.
Charles River Laboratories International Jumps 8.1% in Broad Rally
Charles River Laboratories International (CRL) saw an 8.1% surge on Wednesday, closing at $201.74, driven by a broad sector-wide rally in diagnostics and research companies. This strong performance, outpacing several peers, suggests a reassessment of value in the sector by investors, rather than a response to company-specific news. The synchronized gains among multiple comparable companies indicate renewed investor appetite for the industry, prompting questions about the sustainability of this shift.
How Revvity’s New Signals AI-Powered R&D Platform (RVTY) Has Changed Its Investment Story
Revvity, Inc. has introduced Signals AI into its Signals One platform, aiming to transform R&D data into actionable insights for scientists using natural language. This enhancement strengthens Revvity's software-led investment narrative, emphasizing higher-margin recurring revenue and deeper customer relationships, despite ongoing concerns about regulatory and pricing pressures in China. The company's forecasts project significant revenue and earnings growth by 2029, suggesting a potential 14% upside to its current stock price.
How Revvity’s New Signals AI-Powered R&D Platform (RVTY) Has Changed Its Investment Story
Revvity, Inc. (RVTY) recently launched Signals AI within its Signals One platform, enhancing its R&D capabilities with natural language AI to transform data into scientific understanding. This move strengthens Revvity's software-led investment narrative, aiming to improve growth quality and margins through higher-margin recurring revenue streams. However, persistent regulatory and pricing pressures in China remain a key risk, and analysts hold differing views on the company's future revenue growth and profitability.
WST Stock Price and Chart — NYSE:WST
This page provides an overview of West Pharmaceutical Services, Inc. (WST) stock, including its current price, performance metrics, key financial stats, and company information. It also includes various trading ideas and technical analyses from the TradingView community, along with analyst ratings and ETF holdings.
